An eight-gene blood expression profile predicts the response to infliximab in rheumatoid arthritis

PLoS ONE

Volumn 4, Issue 10, 2009, Pages

  Julià, Antonio ^a   Erra, Alba ^a   Palacio, Carles ^a   Tomas, Carlos ^a   Sans, Xavier ^a   Barceló, Pere ^a   Marsal, Sara ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

INFLIXIMAB; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISOLONE; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; ANTIRHEUMATIC AGENT; INTERLEUKIN 2 RECEPTOR ALPHA; MONOCLONAL ANTIBODY;

ACCURACY; ADULT; ARTICLE; BLOOD ANALYSIS; CD4+ CD25+ T LYMPHOCYTE; CELL POPULATION; CLINICAL ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION PROFILING; HUMAN; LYMPHOCYTE COUNT; MALE; PREDICTOR VARIABLE; RHEUMATOID ARTHRITIS; VALIDATION PROCESS; BIOSYNTHESIS; CD4+ T LYMPHOCYTE; DNA MICROARRAY; METABOLISM; METHODOLOGY; MIDDLE AGED; REPRODUCIBILITY; TREATMENT OUTCOME;

ADULT; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CD4-POSITIVE T-LYMPHOCYTES; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION PROFILING; HUMANS; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; MALE; MIDDLE AGED; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; REPRODUCIBILITY OF RESULTS; TREATMENT OUTCOME;

EID: 70449571942     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0007556     Document Type: Article

References (39)

1. Smolen JS, Aletaha D, Koeller M, Weisman MH, Emery P (2007) New therapies for treatment of rheumatoid arthritis. Lancet 370: 1861-1874.
2. Firestein GS (2003) Evolving concepts of rheumatoid arthritis. Nature 423: 356-361.
3. Julià A, Ballina J, Cañete J, Balsa A, Tornero-Molina J, et al. (2008) Genome-wide association study of rheumatoid arthritis in the Spanish population: KLF12 as a risk locus for rheumatoid arthritis susceptibility. Arthritis Rheum 58: 2275-2286.
4. Elliott MJ, Maini RN, Feldmann M, Kalden JR, Antoni C, et al. (1994) Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet 344: 1105-1110.
5. Strand V, Kimberly R, Isaacs JD (2007) Biologic therapies in rheumatology: lessons learned, future directions. Nat Rev Drug Discov 6: 75-92.
6. Saag KG, Teng GG, Patkar NM, Anuntiyo J, Finney C, et al. (2008) American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum 59: 762-784.
7. Hyrich KL, Watson KD, Silman AJ, Symmons DP (2006) Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Rheumatology (Oxford) 45: 1558-1565.
8. Saleem B, Cox SR, Emery P (2006) Biomarkers: Strategies to predict outcome of rheumatoid arthritis. Drug Discovery Today: Therapeutic Strategies 3: 11-16.
9. van 't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, et al. (2002) Gene expression profiling predicts clinical outcome of breast cancer. Nature 415: 530-536.
10. Ebert BL, Galili N, Tamayo P, Bosco J, Mak R, et al. (2008) An Erythroid Differentiation Signature Predicts Response to Lenalidomide in Myelodysplastic Syndrome. PLoS Medicine 5: e35.
11. Prevoo ML, van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, et al. (1995) Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 38: 44-48.
12. Arnett FC (1989) Revised criteria for the classification of rheumatoid arthritis. Bulletin On the Rheumatic Diseases 38: 1-6.
13. van Gestel AM, Haagsma CJ, van Riel PL (1998) Validation of rheumatoid arthritis improvement criteria that include simplified joint counts. Arthritis Rheum 41: 1845-1850.
14. Klareskog L, Catrina AI, Paget S (2009) Rheumatoid arthritis. Lancet 373: 659-672.
15. Gentleman RC, Carey VJ, Bates DM, Bolstad B, Dettling M, et al. (2004) Bioconductor: open software development for computational biology and bioinformatics. Genome Biol 5: R80.
16. Bolstad BM, Irizarry RA, Astrand M, Speed TP (2003) A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics 19: 185-193.
17. Allison DB, Cui X, Page GP, Sabripour M (2006) Microarray data analysis: from disarray to consolidation and consensus. Nat Rev Genet 7: 55-65.
18. Smolkin M, Ghosh D (2003) Cluster stability scores for microarray data in cancer studies. BMC Bioinformatics 4: 36.
19. Ntzani EE, Ioannidis JP (2003) Predictive ability of DNA microarrays for cancer outcomes and correlates: an empirical assessment. Lancet 362: 1439-1444.
20. Gentleman R, Carey V, Huber W, Irizarry R, Dudoit S (2005) Bioinformatics and Computational Biology Solutions Using R and Bioconductor; Wong W, Gail M, Krickerberg A, Tsiatis A, Samet J, eds. Springer. 465 p.
21. Efron B, Tibshirani J (1998) An Introduction to the Bootstrap: Chapman and Hall.
22. Bryl E, Vallejo AN, Weyand CM, Goronzy JJ (2001) Down-regulation of CD28 expression by TNF-alpha. Journal of Immunology (Baltimore, Md: 1950) 167: 3231-3238.
23. Bach JF (2003) Regulatory T cells under scrutiny. Nat Rev Immunol 3: 189-198.
24. Michiels S, Koscielny S, Hill C (2005) Prediction of cancer outcome with microarrays: a multiple random validation strategy. Lancet 365: 488-492.
25. Mugnier B, Balandraud N, Darque A, Roudier C, Roudier J, et al. (2003) Polymorphism at position -308 of the tumor necrosis factor alpha gene influences outcome of infliximab therapy in rheumatoid arthritis. Arthritis Rheum 48: 1849-1852.
26. Marotte H, Pallot-Prades B, Grange L, Tebib J, Gaudin P, et al. (2006) The shared epitope is a marker of severity associated with selection for, but not with response to, infliximab in a large rheumatoid arthritis population. Ann Rheum Dis 65: 342-347.
27. Mohr S, Liew CC (2007) The peripheral-blood transcriptome: new insights into disease and risk assessment. Trends Mol Med 13: 422-432.
28. Whitney AR, Diehn M, Popper SJ, Alizadeh AA, Boldrick JC, et al. (2003) Individuality and variation in gene expression patterns in human blood. Proc Natl Acad Sci U S A 100: 1896-1901.
29. Batliwalla FM, Li W, Ritchlin CT, Xiao X, Brenner M, et al. (2006) Microarray analyses of peripheral blood cells identifies unique gene expression signature in psoriatic arthritis. Mol Med.
30. Olsen N, Sokka T, Seehorn CL, Kraft B, Maas K, et al. (2004) A gene expression signature for recent onset rheumatoid arthritis in peripheral blood mononuclear cells. Ann Rheum Dis 63: 1387-1392.
31. Lequerre T, Gauthier-Jauneau AC, Bansard C, Derambure C, Hiron M, et al. (2006) Gene profiling in white blood cells predicts infliximab responsiveness in rheumatoid arthritis. Arthritis Res Ther 8: R105.
32. Sekiguchi N, Kawauchi S, Furuya T, Inaba N, Matsuda K, et al. (2008) Messenger ribonucleic acid expression profile in peripheral blood cells from RA patients following treatment with an anti-TNF-alpha monoclonal antibody, infliximab. Rheumatology (Oxford) 47: 780-788.
33. Vignali DA, Collison LW, Workman CJ (2008) How regulatory T cells work. Nat Rev Immunol 8: 523-532.
34. Nadkarni S, Mauri C, Ehrenstein MR (2007) Anti-TNF-alpha therapy induces a distinct regulatory T cell population in patients with rheumatoid arthritis via TGF-beta. J Exp Med 204: 33-39.
35. Lande R, Gregorio J, Facchinetti V, Chatterjee B, Wang YH, et al. (2007) Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide. Nature 449: 564-569.
36. Lodes MJ, Cong Y, Elson CO, Mohamath R, Landers CJ, et al. (2004) Bacterial flagellin is a dominant antigen in Crohn disease. J Clin Invest 113: 1296-1306.
37. Fessler MB, Malcolm KC, Duncan MW, Worthen GS (2002) A genomic and proteomic analysis of activation of the human neutrophil by lipopolysaccharide and its mediation by p38 mitogen-activated protein kinase. J Biol Chem 277: 31291-31302.
38. Ma CS, Nichols KE, Tangye SG (2007) Regulation of cellular and humoral immune responses by the SLAM and SAP families of molecules. Annu Rev Immunol 25: 337-379.
39. Tydell CC, David-Fung ES, Moore JE, Rowen L, Taghon T, et al. (2007) Molecular dissection of prethymic progenitor entry into the T lymphocyte developmental pathway. J Immunol 179: 421-438.